Neurobiology of Aging
Volume 30, Issue 5 , Pages 672-681 , May 2009

The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease

  • Lidia Glodzik-Sobanska

      Affiliations

    • New York University School of Medicine, New York, NY, United States
    • ,
  • Elizabeth Pirraglia

      Affiliations

    • New York University School of Medicine, New York, NY, United States
    • ,
  • Miroslaw Brys

      Affiliations

    • New York University School of Medicine, New York, NY, United States
    • ,
  • Susan de Santi

      Affiliations

    • New York University School of Medicine, New York, NY, United States
    • ,
  • Lisa Mosconi

      Affiliations

    • New York University School of Medicine, New York, NY, United States
    • ,
  • Kenneth E. Rich

      Affiliations

    • New York University School of Medicine, New York, NY, United States
    • ,
  • Remigiusz Switalski

      Affiliations

    • New York University School of Medicine, New York, NY, United States
    • ,
  • Leslie Saint Louis

      Affiliations

    • New York University School of Medicine, New York, NY, United States
    • ,
  • Martin J. Sadowski

      Affiliations

    • New York University School of Medicine, New York, NY, United States
    • ,
  • Frank Martiniuk

      Affiliations

    • New York University School of Medicine, New York, NY, United States
    • ,
  • Pankaj Mehta

      Affiliations

    • Institute for Basic Research, Staten Island, NY, United States
    • ,
  • Domenico Pratico

      Affiliations

    • University of Pennsylvania, Philadelphia, PA, United States
    • ,
  • Raymond P. Zinkowski

      Affiliations

    • Applied NeuroSolutions, Vernon Hills, IL, United States
    • ,
  • Kaj Blennow

      Affiliations

    • University of Goteborg, Sahlgrenska University Hospital, United States
    • ,
  • Mony J. de Leon

      Affiliations

    • New York University School of Medicine, New York, NY, United States
    • Nathan Kline Institute Orangeburg, NY, United States
    • Corresponding Author InformationCorresponding author at: Center for Brain Health, Department of Psychiatry, NYU School of Medicine, 550, New York, NY 10016, United States. Tel.: +1 212 263 5805; fax: +1 212 263 3270.

Received 8 May 2007 ,Revised 10 August 2007 ,Accepted 17 August 2007.

References 

  1. Andreasen N, Vanmechelen E, Van d V, Davidsson P, Hesse C, Tarvonen S, et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J. Neurol. Neurosurg. Psychiatry. 1998;64:298–305
  2. Arai H, Morikawa Y, Higuchi M, Matsui T, Clark CM, Miura M, et al. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem. Biophys. Res. Commun. 1997;236:262–264
  3. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropatholog. 2002;103(1):26–35
  4. Bachman DL, Wolf MD, Linn R, Knoefel JE, Cobb J, Belanger BS, et al. Incidence of dementia and probable Alzheimer's disease in a general population: the Framingham Study. Neurology. 1993;43:515–519
  5. Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66(12):1837–1844
  6. Blennow K. CSF biomarkers for mild cognitive impairment. J. Int. Med. 2004;256:224–234
  7. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet Neurol. 2006;368:387–403
  8. Blennow K, Vanmechelen E. CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry. Brain Res. Bull. 2003;61:235–242
  9. Blomberg M, Jensen M, Basun H, Lannfelt L, Wahlund L-O. Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotien E allele e4 during 14 months follow-up. Neurosci. Lett. 1996;214(2–3):163–166
  10. Blomberg M, Jensen M, Basun H, Lannfelt L, Wahlund LO. Cerebrospinal fluid tau levels increase with age in healthy individuals. Dement. Geriatr. Cogn. Disord. 2001;12:127–132
  11. Briani C, Ruggero S, Naccarato M, Cagnin A, Ricchieri GL, Pasqui L, et al. Combined analysis of CSF +|A42 peptide and tau protein and serum antibodies to glycosaminoglycans in Alzheimer's disease: preliminary data. J. Neural. Trans. 2002;V109(3):393–398
  12. Brys, M., Pirraglia, E., Rich, K., Rolstad, S., Mosconi, L., Switalski, R.,Glodzik-Sobanska, L., De Santi, S., Zinkowski, R., Metha, P.D., Pratico, D., Saint-Louis, L.A., Wallin, A., Blennow, K., de Leon, M.J., 2007. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol. Aging, in press.
  13. Buerger, K., Alafuzoff, I., Ewers, M., Pirttila, T., Zinkowski, R., Hampel, H., 2007. No correlation between CSF tau protein phosphorylated at threonine 181with neocortical neurofibrillary pathology in Alzheimer's disease. Brain, doi:10.1093/brain/awm140.
  14. Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel SJ, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain. 2006;129:3035–3041
  15. Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, et al. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch. Neurol. 2002;59(8):1267–1272
  16. Burkhard PR, Fournier R, Mermillod B, Krauze KH, Bouras C, Irminger I. Cerebrospinal fluid tau and Abeta42 concentrations in healthy subjects: delineation of reference intervals and their limitations. Clin. Chem. Lab. Med. 2004;42:396–407
  17. Chen M, Inestrosa NC, Ross GS, Fernandez HL. Platelets Are the Primary Source of Amyloid [beta]-Peptide in Human Blood. Biochem. Biophys. Res. Commun. 1995;213(1):96–103
  18. De Caterina R, Cipollone F, Filardo FP, Zimarino M, Bernini W, Lazzerini G, et al. Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-a inhibitor simvastatin is accompanied by a related reduction of f2-isoprostane formation in hypercholesterolemic subjects: no further effect of vitamin E. Circulation. 2002;106(20):2543–2549
  19. de Leon MJ, Convit A, Wolf OT, Tarshish CY, De Santi S, Rusinek H, et al. Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET). Proc. Natl. Acad. Sci. USA. 2001;98(19):10966–10971
  20. de Leon, M.J., Mosconi, L., Li, Y., De Santi, S., Yao, Y., Tsui, W.H., Pirraglia, E., Rich, K.E., Javier, E., Brys, M., Glodzik-Sobanska, L., Switalski, R., Saint, L.L., Pratico, D., 2007. Longitudinal CSF isoprostane and MRI measures in the progression to AD. J. Neurol., in press.
  21. Dietrich M, Hu Y, Block G, Olano E, Packer R, Morrow JD, et al. Associations between apolipoprotein E genotype and circulating F2-isoprostane levels in humans. Lipids. 2005;40:329–334
  22. Engelborghs S, Sleegers K, Cras P, Brouwers N, Serneels S, De LE, et al. No association of CSF biomarkers with APOE{varepsilon}4, plaque and tangle burden in definite Alzheimer's disease. Brain. 2007;130(9):2320–2326
  23. Fagan AM, Roe CM, Xiong C, Mintun M, Morris JC, Holtzman DM . Cerebrospinal Fluid tau/beta-Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults. Arch. Neurol. 2007;
  24. Fagan AM, Younkin LH, Morris JC, Fryer JD, Cole TG, Younkin SG, et al. Differences in the Abeta40/Abeta42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. Ann. Neurol. 2000;48(2):201–210
  25. Farrer LA, Cuples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer Disease. JAMA. 1997;278(16):1349–1356
  26. Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch. Neurol. 1998;55(7):937–945
  27. Gilbert JG, Levee RF, Catalano FL. A preliminary report on a new memory scale. Percept. Mot. Skills. 1968;27:277–278
  28. Glodzik-Sobanska L, Rusinek H, Mosconi L, Li Y, Zhan J, De Santi S, et al. The role of quantitative structural imaging in the early diagnosis of Alzheimer's disease. Neuroimaging Clin. N. Am. 2005;15:803–826
  29. Golombowski S, Muller-Spahn F, Romig H, Mendla K, Hock C. Dependence of cerebrospinal fluid Tau protein levels on apolipoprotein E4 allele frequency in patients with Alzheimer's disease. Neurosci. Lett. 1997;225:213–215
  30. Greenow K, Pearce NJ, Ramji DP. The key role of apolipoprotein E in atherosclerosis. J. Mol. Med. 2005;83:329–342
  31. Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, et al. Measurement of Phosphorylated tau epitopes in the differential diagnosis of alzheimer disease: a comparative cerebrospinal fluid study. Arch. Gen. Psychiatry. 2004;61(1):95–102
  32. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5(3):228–234
  33. Itoh N, Arai H, Urakami H, Ishiguro K, Ohno H, Hampel H, et al. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann. Neurol. 2001;50:150–156
  34. Jensen M, Basun H, Lannfelt L. Increased cerebrospinal fluid tau in patients with Alzheimer's disease. Neurosci. Lett. 1995;186:189–191
  35. Khachaturian AS, Corcoran CD, Mayer LS, Zandi PP, Breitner JCS. Apolipoprotein E {epsilon}4 Count Affects Age at Onset of Alzheimer Disease, but Not Lifetime Susceptibility: The Cache County Study. Arch. Gen. Psychiatry. 2004;61(5):518–524
  36. Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ, et al. Neuropathology of cognitively normal elderly. J. Neuropathol. Exp. Neurol. 2003;62(11):1087–1095
  37. Kohnken R, Buerger K, Zinkowski R, Miller C, Kerkman D, DeBernardis J, et al. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci. Lett. 2000;187–190
  38. Lewczuk P, Esselmann H, Bibl M, Beck G, Maler JM, Otto M, et al. Tau protein phosphorylated at threonine 181 in csf as a neurochemical biomarker in Alzheimer's disease. J. Mol. Neurosci. 2004;23:115–122
  39. Lewczuk P, Esselmann H, Otto M, Maler JM, Henkel AW, Henkel MK, et al. Neurochemical diagnosis of Alzheimer's dementia by CSF A[beta]42 A[beta]42/A[beta]40 ratio and total tau. Neurobiol. Aging. 2004;25(3):273–281
  40. Mahley RW, Weisgraber KH, Huang J. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. PNAS. 2006;103:5644–5651
  41. Main BF, Jones PJ, MacGillivray RT, Banfield DK. Apolipoprotein E genotyping using the polymerase chain reaction and allele-specific oligonucleotide primers. J. Lipid Res. 1991;32:183–187
  42. Metha PD, Pirttila T, Metha SP, Sersen E, Aisen PS, Wisnewski HM. Plasma and cerebrospinal fluids levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer's disease. Arch. Neurol. 2000;57:100–105
  43. Mitchell A, Brindle N. CSF phosphorylated tau—does it constitute an accurate biological test for Alzheimer's disease?. Int. J. Geriatr. Psychiatry. 2003;18(5):407–411
  44. Mollenhauer B, Bibl M, Trenkwalder C, Stiens G, Cepek L, Steinacker P, et al. Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimers disease. J. Neural. Trans. 2005;112(7):933–948
  45. Mori H, Hosoda K, Matsubara E, Nakamoto T, Furiya Y, Endoh R, et al. Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau. Neurosci. Lett. 1995;186(2–3):181–183
  46. Mosconi L, Reiman EM, Tsui WH, Chen K, De Santi S, Li Y, Caselli RJ, Alexander G, de Leon MJ. Reduced brain glucose metabolism predicts cognitive decline in normal ApoE E4 carriers. in prep 2007.
  47. Ohm TG, Scharnagl H, Marz W, Bohl J. Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer's disease-related lesions. Acta Neuropathol. 1999;98:273–280
  48. Peskind ER, Li G, Shofer J, Quinn JF, Kaye JA, Clark CM, et al. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal. Cogn. Arch. Neurol. 2006;63(7):936–939
  49. Pratico D, Clark CM, Lee VM, Trojanowski JQ, Rokach J, Fitzgerald GA. Increased 8.12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann. Neurol. 2000;48(5):809–812
  50. Pratico D, Clark CM, Liun F, Lee VY, Trojanowski JQ. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch. Neurol. 2002;59(6):972–976
  51. Ramassamy C, Averill D, Beffert U, Theroux L, Lussier-Cacan S, Cohn JS, et al. Oxidative Insults are associated with apolipoprotein E genotype in alzheimer's disease brain. Neurobiol. Dis. 2000;7(1):23–37
  52. Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the E4 allele for apolipoprotein E. N. Engl. J. Med. 1996;334(12):752–758
  53. Reisberg B, London E, Ferris SH, Borenstein J, Scheier L, de Leon MJ. The Brief Cognitive Rating Scale: Language, motoric, and mood concomitants in primary degenerative dementia. Psychopharmacol. Bull. 1983;19:702–708
  54. Reisberg B, Sclan SG, Franssen EH, de Leon MJ, Kluger A, Torossian CL, et al. Clinical stages of normal aging and Alzheimer's disease: the GDS staging system. Neurosci. Res. Commun. 1993;13(Suppl. 1):551–554
  55. Rusinek H, De Santi S, Frid D, Tsui W, Tarshish C, Convit A, et al. Regional brain atrophy rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging. Radiology. 2003;229:691–696
  56. Shoji M, Matsubara E, Kanai M, Watanabe M, Nakamura T, Tomidokoro Y, et al. Combination assay of CSF Tau, Aβ1–40 and Aβ1–42(43) as a biochemical marker of Alzheimer's disease. J. Neurol. Sci. 1998;158(2):134–140
  57. Sjogren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, Wikkelso C, et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin. Chem. 2001;47(10):1776–1781
  58. Sultana R, Perluigi M, Butterfield DA. Protein Oxidation and lipid peroxidation in brain of subjects with Alzheimer's disease: Insights into Mechanism of neurodegeneration from redox proteomics. Antioxid. Redox Signal. 2006;8(11–12):2021–2037
  59. Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, et al. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Biol. Psychiatry. 2004;56:670–676
  60. Sutherland WHF, Manning PJ, Walker RJ, de Jong SA, Ryalls AR, Berry EA. Vitamin E Supplementation and Plasma 8-Isoprostane and Adiponectin in Overweight Subjects. Obesity. 2007;15(2):386–391
  61. Uylings HBM, de Brabander JM. Neuronal Changes in Normal Human Aging and Alzheimer's disease. Brain Cogn. 2002;49:268–276
  62. Wechsler D. WAIS-R Manual. New York: Psychological Corporation; 1981;
  63. Wiltfang J, Esselmann H, Bibl M, Hull M, Hampel H, Kessler H, et al. Amyloid beta peptide ratio 42/40 but not Abeta42 correlates with phospho-Tau in patients with low- and high-CSF Abeta40 load. J. Neurochem. 2007;101(4):1053–1059
  64. Xhignesse M, Lussier-Cacan S, Sing CF, Kessling AM, Davignon J. Influences of common variants of apolipoprotein E on measures of lipid metabolism in a sample selected for health. Arterioscler. Thromb. 1991;11:1100–1110
  65. Zhu X, Raina AK, Lee HG, Chao M, Nunomura A, Tabaton M, et al. Oxidative stress and neuronal adaptation in Alzheimer disease: the role of SAPK pathways. Antioxid. Redox Signal. 2003;5:571–576

PII: S0197-4580(07)00349-1

doi: 10.1016/j.neurobiolaging.2007.08.019

Neurobiology of Aging
Volume 30, Issue 5 , Pages 672-681 , May 2009

Article Tools

* Image Usage & Resolution